A long-term study of people with neurofibromatosis type 2 and how their tumors and symptoms change
Original title: Natural History Study of Patients With Neurofibromatosis Type 2
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed for this study, and it is watching and measuring people over time rather than testing a treatment.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study follows people with neurofibromatosis type 2 over time to learn why tumors and nerve problems get worse.
Who this trial is for. This study is for people ages 8-75 who have neurofibromatosis type 2 (NF2), confirmed by a doctor's diagnosis or by genetic testing. It plans to include 269 participants, who get exams, MRI scans of the brain and spine, blood tests, and hearing, balance, speech, and swallowing checks, then return for the same kind of checks each year for up to ten years.
Where it stands. This study does not test a new treatment. It is collecting information to look for links between MRI findings, exam results, nerve problems, hearing loss, and speech and swallowing trouble in NF2. It is also looking for signs in the blood tied to a higher tumor burden. The study has not reported results.
What this means, and what it doesn't
What it could mean: Nothing here changes your care today. Joining would mean regular testing and follow-up, not a new therapy. Someone with NF2 who is interested could ask their care team whether this study is worth looking into.
What it doesn't mean: This does not mean a new treatment is available. A study is a way to gather information, not proven care. Taking part is not a guarantee that anything will help you, and it is not a promise of a cure. Whether anyone can join is decided by the study team.
Source: ClinicalTrials.gov, August 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.